Onconic Therapeutics: "Nesuparib Shows 133 Times Greater Inhibition Than Olaparib in Small Cell Lung Cancer"
Selected for Two Preclinical Presentations at AACR 2026
Efficacy Demonstrated in Pancreatic Cancer Regardless of BRCA Mutation Status
Onconic Therapeutics' anticancer drug candidate 'Nesuparib' will have two sets of preclinical study results on small cell lung cancer and pancreatic cancer presented at an international conference.
On March 18, Onconic Therapeutics announced that two studies related to Nesuparib have been selected for poster presentations at the American Association for Cancer Research (AACR) 2026, which will take place next month in San Diego, USA. The study abstracts have been released through the conference.
In cell experiments for small cell lung cancer, Nesuparib demonstrated up to 133 times greater cancer cell growth inhibition compared to the existing PARP inhibitor olaparib, and approximately 25 times greater than irinotecan. In animal models, it recorded a tumor inhibition rate of 66.5%, surpassing olaparib (36%) and irinotecan (42.9%).
In the pancreatic cancer preclinical study, antitumor effects were observed regardless of BRCA mutation status. In cell experiments, when combined with standard treatments (gemcitabine and nab-paclitaxel), cancer cell viability decreased by more than 70%. In animal models, combination therapy reduced tumor size by 79%, showing a stronger inhibitory effect compared to monotherapy (31%).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Nesuparib is based on a dual mechanism that inhibits both PARP and tankyrase simultaneously. The company plans to continue the ongoing phase 2 clinical development for pancreatic cancer based on these results.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.